Subject of the day
ALKS
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
FY 2011–2025 · 14 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $1.48B | +10.8% | |
| Operating income | $253.96M | -38.7% | |
| Net income | $241.66M | +139.2% | |
| Cash from ops | $439.12M | +56.4% |
$49.45
▼ -0.83 (-1.7%)
| 52w hi | $55.22 |
|---|---|
| 52w lo | $26.52 |
| Vol | 1.53M |
| As of | Aug 13 |
Our score +0.59
| Short | +0.75 |
|---|---|
| Medium | +0.74 |
| Long | -0.02 |
computed 2026-08-13
Alkermes plc
Healthcare · Drug Manufacturers - Specialty & Generic
| Market cap | $8.30B |
|---|---|
| Enterprise value | $9.35B |
| Trailing P/E | 130.13x |
| Forward P/E | 27.05x |
| EV / EBITDA | 32.82x |
| P / S (ttm) | 4.97x |
| Profit margin | 4.0% |
| Return on equity | 3.9% |
| Revenue growth | +27.0% |
| Earnings growth | -99.4% |
| Debt / equity | 86.95 |
| Beta vs SPX | 0.72 |
|---|---|
| Corr SPX | 0.31 |
| Annual vol | 37.8% |
| Annual ret | +37.8% |
| Sharpe | 1.00 |
| Max DD | -27.4% |
Window: 504 trading days (504 obs)
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | -0.02 | |
| Sector | +0.12 | |
| Technical | +0.50 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-08-13
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Aug 13 | $51.66 | $51.11 | $49.21 | $49.45 | 1.53M |
| Aug 12 | $49.22 | $50.53 | $48.50 | $50.28 | 1.32M |
| Aug 11 | $49.92 | $50.14 | $48.97 | $49.21 | 1.37M |
| Aug 10 | $48.39 | $49.81 | $48.39 | $49.40 | 1.51M |
| Aug 7 | $49.05 | $49.90 | $48.67 | $49.17 | 1.11M |